WebApr 11, 2024 · Led by Dr. Darren Wong with the guidance of Assoc. Prof. Low Boon Chuan, the team discovered how BPGAP1 synchronizes two key proteins responsible for cell migration—namely, GTPases Rac1 and RhoA ... WebNational Center for Biotechnology Information
Aurora Kinase Inhibitor LY3295668 in Combination With …
WebLY3295668, an AURKA inhibitor with over 1,000-fold selectivity versus AURKB, is distinguished by minimal toxicity to bone marrow cells at concentrations active against RB1 mut cancer cells. In vivo: LY3295668 … WebLY3295668 inhibits the growth of a broad panel of cancer cell lines, including small-cell lung and breast cancer cells. It demonstrates significant efficacy in small-cell lung cancer xenograft and patient-derived tumor preclinical models as a single agent and in combination with standard-of-care agents. LY3295668, as a highly Aurora A ... cf40tddc
Aurora A selective inhibitor LY3295668 leads to dominant
WebNov 1, 2024 · Recently, a highly selective AURKA inhibitor, LY3295668, which potently inhibits proliferation in a broad panel of cancer cell lines, was shown to induce apoptosis and to be highly effective in xenograft and PDX pre-clinical tumor models. These successes have prompted the selection of LY3295668 for phase I clinical trials in high-risk relapsed ... WebNov 6, 2024 · LY3295668 and cisplatin were purchased from Selleck Chemicals (Shanghai, China). 2.2 Cell viability assay Cell viability was determined using the CellTiter-Glo (CTG) luminescent cell viability assay kit (G5750, Promega) according to the … WebLY3295668 is a selective inhibitor of Aurora A with Kis of 0.8 nM and 1038 nM for Aurora A and B, respectively. All products from TargetMol are for Research Use Only. Not for … b. what are expansion slots used for